Table 2. Clinical Characteristics of the Patients According to the Number of Kawasaki’s Disease–like Features Present.*.
| Characteristic | Patients with 4 or 5 Features (N=38) |
Patients with 2 or 3 Features plus Laboratory Findings (N=36) |
Other (N=112)† |
All Patients (N=186) |
|---|---|---|---|---|
| Median age (IQR) — yr | 5.7 (1.7–8.9) | 8.4 (4.2–12.0) | 9.1 (3.1–14.1) | 8.3 (3.3–12.5) |
| Signs and symptoms | ||||
| Fever‡ | 38 (100) | 36 (100) | 112 (100) | 186 (100) |
| Median fever duration (IQR) — days | 6 (6–8) | 6 (6–8) | 6 (4–8) | 6 (5–8) |
| Fever duration — no./total no. (%) | ||||
| ≤3 days | 0 | 0 | 16/93 (17) | 16/167 (10) |
| 4 days | 0 | 0 | 20/93 (22) | 20/167 (12) |
| ≥5 days | 38/38 (100) | 36/36 (100) | 57/93 (61) | 131/167 (78) |
| Bilateral conjunctival injection — no. (%) | 36 (95) | 30 (83) | 37 (33) | 103 (55) |
| Oral mucosal changes — no. (%) | 38 (100) | 16 (44) | 24 (21) | 78 (42) |
| Peripheral extremity changes — no. (%) | 36 (95) | 14 (39) | 19 (17) | 69 (37) |
| Rash — no. (%) | 38 (100) | 27 (75) | 45 (40) | 110 (59) |
| Cervical lymphadenopathy >1.5 cm diameter — no. (%)§ | 7 (18) | 3 (8) | 8 (7) | 18 (10) |
| Echocardiography performed — no. (%) | 37 (97) | 35 (97) | 98 (88) | 170 (91) |
| LAD or RCA z score of ≥2.5¶ | 3 (8) | 8 (23) | 4 (4) | 15 (9) |
| Treatment | ||||
| Intravenous immune globulin — no. (%) | 38 (100) | 35 (97) | 71 (63) | 144 (77) |
| Median day of illness on which treatment was received (IQR) | 6 (6–8) | 7 (6–8) | 6 (5–8) | 6 (5–8) |
| Second dose received — no. (%) | 16 (42) | 9 (25) | 14 (12) | 39 (21) |
| Systemic glucocorticoid — no. (%) | 20 (53) | 18 (50) | 53 (47) | 91 (49) |
| Interleukin-6 inhibitor — no. (%)‖ | 1 (3) | 1 (3) | 12 (11) | 14 (8) |
| Interleukin-1Ra inhibitor — no. (%)** | 5 (13) | 6 (17) | 13 (12) | 24 (13) |
| Anticoagulation therapy — no. (%)†† | 14 (37) | 18 (50) | 55 (49) | 87 (47) |
| Highest level of care | ||||
| Ward — no. (%) | 13 (34) | 2 (6) | 23 (21) | 38 (20) |
| Intensive care unit — no. (%) | 25 (66) | 34 (94) | 89 (79) | 148 (80) |
Kawasaki’s disease–like features are listed in Table S2 in the Supplementary Appendix. The number of features excludes fever. IQR denotes interquartile range, LAD left anterior descending, and RCA right coronary artery.
This category includes patients who had 0 or 1 Kawasaki’s disease–like features or 2 or 3 features without additional laboratory findings.
Fever was defined as a body temperature higher than 38.0°C.
Data on cervical lymphadenopathy were not collected systematically for patients with fewer than two principal signs of Kawasaki’s disease.
The denominator for the calculation of these percentages was the number of patients who had echocardiography performed.
Interleukin-6 inhibitors included tocilizumab and siltuximab.
The interleukin-1Ra inhibitor given was anakinra.
Anticoagulation therapy included heparin, enoxaparin, bivalirudin, warfarin, and argatroban.